



1 network for Clinical Cancer Research with a global impact



### research groups

conduct cross-center clinical cancer studies across all types of cancer and all disciplines throughout Switzerland



### young oncologists who joined the Young Oncology Academy 2024 to make contributions

to oncology

active clinical trials - thereof 27 actively recruiting



**69 employees** -a dedicated team with 58.3 full-time positions-make an effort for better chances of recovery and improved quality of life for patients



scientific articles published, 18 poster presentations and 23 oral presentations at major oncology congresses



8 awards for cancer research projects, honored by SAKK and partners



patients newly recruited into trials in 2024, trusted in our research and participated in our trials. Thank you!

**SAKK projects** and four external research ideas were discussed with the Patient Advisory Board

### Contents

Goals	
Editorial by the President	4
Together	
Editorial by the CFO	5
Our Donors	6
Promoting Dialog	7
Organization Chart	8

GOALS

#### **Financial Statements**

Balance Sheet	9
Statement of Operations	10
Cash Flow Statement	11
Statement of Changes in Capital	12
Statement of Changes in Funds	13

#### Annex

Notes to the 2024 Annual Financial Statements	14
Auditor's Report	17
Publishing Details	19



#### **Annual Portrait**

The Financial Report is published as an addendum to the Annual Portrait. This reports on the events of 2024 and provides an insight into SAKK's activities.

OGETHER

### Making Meaningful Progress in the Fight Against Cancer

2024 has been marked by stable financial success, a strong commitment to our collaborations and our mission. Introducing a lean academic trial module was a major milestone in improving research efficiency.



SAKK is pleased to report that, for the third consecutive year, we have closed our financial year with a positive result, an important milestone in our ongoing financial recovery.

This success has only been possible thanks to the continued support of our main grant providers: the State Secretariat for Education, Research and Innovation (SERI), Swiss Cancer Research and the Rising Tide Foundation. We extend our heartfelt gratitude to these institutions. Equally important was the dedication of our Board members, particularly the financial commission, whose strategic oversight has been instrumental in achieving financial stability. We also acknowledge the special efforts of our new CEO and the entire staff at the Competence Center, whose outstanding commitment have significantly contributed to our financial performance.

The solid financial standing has allowed us to reinvest in critical clinical trial activities. In 2025, we plan to open 21 new studies, reinforcing our commitment to stay Switzerland's leading clinical cancer research institution. We also initiated discussions with the Swiss National Science Foundation (SNSF) and Swiss Cancer Research to explore ways to further promote clinical cancer research. As a result, we are developing a new funding strategy together with Swiss Cancer Research to help both organizations create additional financial support.

Strengthening our relationships with key stakeholders has been another focus this year. We have made significant strides in establishing connections with health insurers to explore their contributions to clinical cancer research. Furthermore, we have engaged with the Swiss Conference of the Cantonal Health Directors to discuss potential cantonal support.

A major milestone in our efforts to improve research efficiency has been the initiation of a lean academic trial module. This innovative concept is designed to streamline processes, significantly reduce costs and increase transparency, thus providing financial and scientific advantages to researchers and patients alike. Over the next few months, we will be testing this modular approach.

Looking ahead, we are confident that our strengthened financial position, strategic partnerships and innovative research approaches will enable us to expand opportunities within our network. Our ultimate goal remains clear: advancing clinical cancer research to benefit all cancer patients in Switzerland. With our collective efforts and the support of our stakeholders, we are well-positioned to make meaningful progress in the fight against cancer.

**Prof. Dr. med. Miklos Pless** SAKK Board President

ANNEX

### Committed to the Future

For the third year in a row, SAKK has achieved a positive balance. In addition to the stable operating result, our financial assets performed well. A large legacy donation further ensures financial stability and confirms our positive public perception.

For the third consecutive year, SAKK has achieved a positive financial balance, reinforcing the stability and sustainability of our organization. In addition to a stable operating result, our financial assets performed exceptionally well, reflecting prudent management and a well-diversified investment strategy.

A particularly noteworthy development in 2024 was the receipt of a significant legacy donation, which serves as a testament to the positive public perception of SAKK and the trust we have built over the years. This generous contribution, along with other financial inflows, ensures stable and secure funding for 2025 and beyond. With this strong financial foundation, we can expand our initiatives, invest in pioneering research, and further develop innovative treatment approaches that benefit cancer patients in Switzerland.

Beyond financial success, we have worked diligently to refine and optimize our internal processes, ensuring that our operations remain efficient and effective. One of the key advancements in this area has been the development of a new and comprehensive fundraising strategy. This strategy will help us to broaden our sources of income even further. As a result, we are financially well-equipped for the future, always committed to our core mission of bringing progress to cancer care and providing cancer patients in Switzerland with innovative treatment options. Through our research projects, we continue to optimize therapies, enhancing both the effectiveness and accessibility of treatment options. This not only improves the chances of recovery for cancer patients but also contributes to extending life expectancy and enhancing the overall quality of life for those affected by this disease.

#### Stefan Demetz

CFO



### Legacy donation ensures financial stability for SAKK.

Stefan Demetz, CFO

### Our Donors

Public sector and third parties Alfred und Anneliese Sutter-Stöttner Stiftung All Can Switzerland Association Cancer League Switzerland (Krebsliga) City of Zurich Hedy Glor-Meyer Stiftung Klinikum der Universität München MediCongress GmbH Norges teknisk-naturvitenskapelige universitet NTNU PlayToKnow AG SOHC Board of Trustees Swiss Oncology & Hematology State Secretariat for Education, Research and Innovation SERI Swiss Cancer Research Foundation Swiss Foundation for Clinical Cancer Research SSKK Swiss Paediatric Oncology Group SPOG Swiss Personalized Health Network (SPHN) Unicancer - Federation of Cancer Centers University of Basel University of Bern University of Zurich

#### Industry

AbbVie AG Switzerland Accord Healthcare AG Amgen Switzerland AG Astellas Pharma AG Switzerland Astellas Pharma Europe Ltd. AstraZeneca AG Bayer (Schweiz) AG, Zurich Bayer Consumer Care AG BeiGene Switzerland GmbH Bilthoven Biologicals B.V. Breastceuticals AG Bristol-Myers Squibb SA Daiichi Sankyo (Switzerland) AG Eli Lilly (Suisse) SA F. Hoffmann-La-Roche Ltd. Fédération Francophone de Cancérologie Digestive FFCD Gilead Sciences Switzerland Sarl GlaxoSmithKline AG Helvepharm AG **IDEOGEN AG** Immunophotonics Inc. Incyte Biosciences International Sàrl InnoMedica Schweiz AG Intensity Therapeutics, CT **IPSEN Pharma Schweiz GmbH** Janssen Pharmaceutica NV Janssen-Cilag AG Merck (Schweiz) AG MSD Merck Sharp & Dohme AG Myriad Genetics GmbH Novartis Pharma Schweiz AG Nurix Therapeutics Inc., CA PEAK Medicals GmbH Pfizer AG Pharma Mar SA Pierre Fabre Pharma AG **Release Therapeutics** Roche Pharma (Schweiz) AG Sanofi-Aventis (Schweiz) AG Servier (Suisse) S.A. Stemline Therapeutics Switzerland GmbH Takeda Pharma AG

#### International research groups

ABCSG Research Services GmbH AGO Research GmbH ETOP IBCSG Partners Foundation European Organization for Research and Treatment of Cancer (AISBL/IVZW) EORTC Exact Sciences International GmbH GHSG Studienzentrale HOVON Stichting IRCCS – Istituto di Ricerche Farmacologiche Mario Negri LYSARC, The Lymphoma Academic Research Organization Novocure GmbH St. Clara Forschung AG

Additional donations from our members Cantonal Hospital Aarau AG Cantonal Hospital Baden AG Cantonal Hospital Fribourg HFR Cantonal Hospital Graubünden Cantonal Hospital St.Gallen Cantonal Hospital Winterthur Charité – University Medicine Berlin Geneva University Hospitals HUG Hôpital du Valais Hug Oncology Department Insel Gruppe AG Istituto di Imaging Della Svizzera Italiana (IIMSI) Landeskrankenhaus Feldkirch Lausanne University Hospital (CHUV) LUKS Spitalbetriebe AG Oncology Institute of Southern Switzerland (IOSI) Onkozentrum Zurich Réseau Hospitalier Neuchâtelois (RHNe) Solothurner Spitäler AG Spital STS AG Thun Spital Thurgau AG Spitalzentrum Biel AG University Hospital Basel University Hospital Zurich University Medical Center of J. Gutenberg University Mainz University of Geneva

# **Promoting Dialog**

SAKK advances the development of effective cancer treatments by collaborating and hosting initiatives such as training, events and symposia that open new perspectives for treatment.

At meetings held in parallel with the ESMO and ASCO congresses, participants explored innovative approaches in cancer research. Introductory courses in Lausanne and St. Gallen deepened participants' understanding of genetic counseling in oncology. At the semi-annual meeting in June, SAKK presented six awards in collaboration with other partners. The Patient Advisory Board's engagement in various events proved to be highly valuable. Notably, their participation in the inaugural Swiss Symposium on Patient and Public Participation/ Engagement (PPIE) in healthcare was particularly significant.

At its semi-annual meeting held at the Lucerne Culture and Convention Centre, SAKK presented five awards and one research grant worth a total of CHF 1,160,000 to particularly promising studies relating to clinical cancer research.

- SAKK/AbbVie Digital Innovation Award
- SAKK/Astellas GU-Oncology Award
- SAKK/BMS HEM Pioneer Grant
- SAKK/Gilead Expanding Horizons in Oncology Award
- SAKK/Novartis Together for Patients Award
- SAKK Network Trial Award 2023-2024

January 13, 2024 **GU Cancer Forum** Zurich

January 16, 2024 **GU Cancer Forum** Lausanne

January 30, 2024 SAKK Training Course for CRCs and CTNs Bern

February 22, 2024 Forum dei pazienti Lugano

February 23–24, 2024 Introductory Course in Genetic Counseling in Oncology St. Gallen

March 13, 2024 GU Cancer Forum Lugano

#### May 17, 2024

Swiss Consensus Conference for functional and oncological follow-up after cystectomy and trimodal therapy Lucerne

June 06–08, 2024 **Chicago in the Mountains** Flüeli-Ranft

June 25–27, 2024 SAKK Semi-Annual Meeting Lucerne

August 15, 2024 Post APCCC Bern

August 22, 2024 Industry Pool Meeting Bern


August 29, 2024 SAKK Training Course for CRCs and CTNs Bern September 06–07, 2024 Introductory Course in Genetic Counseling in Oncology Lausanne

September 25, 2024 ESMO in the Alps Lucerne

November 07–08, 2024 5<sup>th</sup> Swiss SAKK Translational Urogenital Cancer Network Meeting & Award - SAKK / Astellas & AstraZeneca GU Research Award - SAKK / Novartis Prostate Cancer Award Bern

November 20–22, 2024 SOHC/SAKK Semi-Annual Meeting Basel \_

### **Organization Chart** SAKK



\_

# **Balance Sheet**

As at December 31	A	2024		2022	
in CHF	Annex	2024		2023	
Assets					
Cash and cash equivalents		9,954,588		9,825,861	
Accounts receivable	1)	1,566,340		1,433,782	
Other accounts receivable		386,099		68,973	
Prepaid expenses and accrued income	2)	546,008		650,686	
Total current assets		12,453,035	33.6%	11,979,302	36.5%
Financial assets	3)	24,582,684		20,801,398	
Total fixed assets		24,582,684	66.4%	20,801,398	63.5%
Total assets		37,035,719	100.0%	32,780,700	100.0%

As at December 31					
in CHF	Annex	2024		2023	
Liabilities					
Accounts payable	4)	1,738,802		2,069,126	
Accrued liabilities and deferred income	5)	18,041,048		16,901,190	
Total short-term liabilities		19,779,850	53.4%	18,970,315	57.9%
Other provisions		242,398		251,036	
Total long-term liabilities		242,398	0.7%	251,036	0.8%
"Special purpose" fund		145,932		270,932	
"Hubacher" fund		10,275,984		9,429,490	
Total special purpose fund capital		10,421,916	28.1%	9,700,422	29.6%
Organizational capital					
Free capital as at January 1		3,858,927		3,768,544	
Group result		2,732,628		90,383	
Free capital as at December 31		6,591,555		3,858,927	
Total organizational capital		6,591,555	17.8%	3,858,927	11.8%
Total liabilities		37,035,719	100.0%	32,780,700	100.0%

# Statement of Operations

January 1 to December 31 in CHF A	nnex	2024		2023	
Operating income					
Research contributions SERI		5,664,390		5,805,172	
Research contributions KLS		-		-57,400	
Research contributions KFS		887,285		1,043,878	
Research contributions SSKK		55,000		128,500	
Research contributions, third parties		468,159		164,255	
Research contributions, Swiss health insurers		218,774		1,785,348	
Income from industry partnerships		6,134,777		4,309,408	
Income from foreign trial groups		144,756		565,484	
Income from Patient Advisory Board		14,706		54,097	
Donations, bequests, legacies		2,662,778		236,727	
Miscellaneous income		2,110,991		1,608,639	
Losses on receivables		-21,642		61,189	
Total operating income		18,339,975	100.0%	15,705,297	100.0%
Operating costs					
Miscellaneous trial-related expenses		-1,727,768		-1,051,446	
Research contributions, sites		-3,438,147		-3,185,436	
Events, congresses and hospitality expenses		-1,291,698		-1,330,209	
Other operating expenses		-66,321		108,959	
Total operating expenses		-6,523,934	-35.6%	-5,458,132	-34.8%
Interim result 1		11,816,041	64.4%	10,247,166	65.2%

January 1 to December 31					
in CHF	Annex	2024		2023	
Coordination expenses					
Personnel expenses	6)	-8,481,757		-8,683,797	
Other coordination expenses		-1,525,815		-1,439,013	
Advertising expenses		-233,694		-366,339	
Total coordination expenses		-10,241,267	-55.8%	-10,489,149	-66.8%
Interim result 2		1,574,775	8.6%	-241,983	-1.5%
Financial result					
Financial income		1,341,272		590,284	
Financial expenses		-183,419		-257,918	
Total financial result		1,157,853	6.3%	332,366	2.1%
Interim result 3		2,732,628	14.9%	90,383	0.6%
Out-of-period result					
Out-of-period income		_		_	
Out-of-period expenses		-		_	
Total out-of-period result		-	0.0%	-	0.0%
Annual result		2,732,628	14.9%	90,383	0.6%

# Cash Flow Statement

January 1 to December 31 in CHF	2024	2023
		2020
+/- Annual gain (+) / loss (-)	2,732,628	90,383
+/- Depreciation/value adjustments (+) and additions (-) to fixed assets / appreciation	-3,781,286	-5,031,550
+/- Recognition (+) and reversal (-) of provisions	-8,638	251,036
+/- Depreciation (+) and appreciation (-) of listed short-term assets	_	_
+/- Decrease (+) / increase (-) in short-term receivables	-449,684	196,361
+/- Decrease (+) / increase (-) in prepaid expenses	104,678	657,323
+/- Increase (+) / decrease (-) in short-term liabilities	-330,324	93,985
+/- Increase (+) / decrease (-) in deferred income	1,139,858	1,073,375
+/- Other cash flow-neutral expenses (+) and income (-)	721,494	641,040
= Cash flow from operating activities	128,726	-2,028,046
– Investments in financial assets	_	_
+ Divestment of financial assets	_	_
= Cash flow from investing activities	-	-
+/– Assumption (+) / repayment (–) of short- and long-term financial liabilities	_	_
+/- Capital increases (+) / repayments (-)	-	-
= Cash flow from financing activities	-	-
Increase or decrease in cash and cash equivalents	128,726	-2,028,046

January 1 to December 31 in CHF	2024	2023
Change in cash and cash equivalents		
As at start of reporting year	9,825,861	11,853,908
As at end of reporting year	9,954,588	9,825,861
Increase (+) / decrease (-) in cash and cash equivalents	128,726	-2,028,046

# Statement of Changes in Capital

			Value fluctuation	
		Net profit (+)	reserve	
In CHF	Free capital	Net loss (–)	Securities	Total
2024				
Holding January 1, 2024	3,858,927	_	_	3,858,927
Change in reserves	_	_	_	-
Annual result	2,732,628	_	_	2,732,628
Holding December 31, 2024	6,591,555	_	_	6,591,555
In CHF	Free capital	Net profit (+) Net loss (–)	Value fluctuation reserve Securities	Total
2023				
Holding January 1, 2023	3,768,544		_	3,768,544
Change in reserves	_	_	_	-
Annual result	90,383	_	_	90,383
Holding December 31, 2023	3,858,927	_	-	3,858,927

### Statement of Changes in Funds

	"Education Grant"	"Special purpose"	"Hubacher"	
In CHF	fund <sup>1</sup>	fund <sup>2</sup>	fund <sup>3</sup>	Total
2024				
Holding January 1, 2024	_	270,932	9,429,490	9,700,422
Fund creation	_	_	_	-
Fund income	_	_	846,494	846,494
Fund costs	_	-	_	-
Fund use	_	-125,000	-	-125,000
Holding December 31, 2024	_	145,932	10,275,984	10,421,916
In CHF	"Education Grant" fund¹	"Special purpose" fund²	"Hubacher" fund <sup>3</sup>	Total
2023				
Holding January 1, 2023	35,000	217,932	8,806,449	9,059,382
Fund creation	_	53,000	_	53,000
Fund income	_	-	623,040	623,040
Fund costs	_	-	-	-
Fund use	-35,000	_	_	-35,000
Holding December 31, 2023	_	270,932	9,429,490	9,700,422

<sup>1</sup> Fund for Janssen-Cilag AG research grant.

<sup>2</sup> Fund for non-industry-associated clinical trials, translational research and training of research specialists.

<sup>3</sup> Fund from the bequest of Dr. Margaretha Hubacher specifically for non-Hodgkin lymphoma research.

# Notes to the 2024 Annual Financial Statements

SAKK is an association based in Bern. These annual financial statements have been prepared in accordance with the requirements of Swiss law, in particular the articles on commercial accounting and financial reporting in the Swiss Code of Obligations (Art. 957 to 962).

As at December 31	2024	2023
Headcount		
Bandwidth of full-time equivalents	> 50	> 50
(average for year)	to 250	to 250
As at December 31 in CHF	2024	2023
Disclosures on, breakdown of and commentary on		
the balance sheet and income statement     Accounts receivable		
T Accounts receivable		
	ess specific valuation allowan	ces. A general
valuation allowance is recognized for the remainder.	ess specific valuation allowan 1,702,793	ces. A general 1,552,671
valuation allowance is recognized for the remainder. Outstanding accounts receivable gross		, and the second s
valuation allowance is recognized for the remainder. Outstanding accounts receivable gross Allowance for doubtful accounts	1,702,793	1,552,671
valuation allowance is recognized for the remainder. Outstanding accounts receivable gross Allowance for doubtful accounts Net accounts receivable	1,702,793 -136,453	1,552,671 -118,889
valuation allowance is recognized for the remainder. Outstanding accounts receivable gross Allowance for doubtful accounts <b>Net accounts receivable</b> 2 Prepaid expenses and accrued income	1,702,793 -136,453 <b>1,566,340</b>	1,552,671 -118,889 <b>1,433,782</b>
Accounts receivable are generally carried at their nominal amount levaluation allowance is recognized for the remainder. Outstanding accounts receivable gross Allowance for doubtful accounts Net accounts receivable 2 Prepaid expenses and accrued income Prepaid expenses and accrued income consist mainly of: Accrued income for trial SAKK 96/12	1,702,793 -136,453 <b>1,566,340</b>	1,552,671 -118,889 <b>1,433,782</b>

As at December 31 in CHF	2024	2023
3 Financial assets	24,582,684	20,801,398
Of which securities "Hubacher" fund	10,179,815	9,390,375

Financial assets are carried at their current market value. The SAKK investment rules were taken into account when investing. Fixed assets are managed externally by Swiss banks.

#### 4 Accounts payable

Accounts payable are carried at their nominal amount.

5 Accrued liabilities and deferred income	18,041,048	16,901,190
Accrued liabilities and deferred income are made up mainly	of the following items:	
Contributions SAKK 96/12	456,523	447,179
Compensation, sites SAKK 96/12	232,635	168,253
Future payments	1,264,035	1,163,334

Future payments	1,264,035	1,163,334
Ongoing trial accruals and deferrals	13,555,241	11,998,998

Trial accruals and deferrals comprise all active trials which, according to cost center accounting, show an amount of prefinancing or a profit. The trial accruals and deferrals were recognized as liabilities in order to cover measurement risks. The other accruals and deferrals are general accruals/deferrals to ensure that income and expenses are recognized appropriately in the period in which they arise.

\_\_\_\_

0

1,955

\_

January 1 to December 31 in CHF	2024	2023
6 Personnel expenses		
Gross salaries	7,007,982	7,268,009
Third-party salaries	180,323	62,841
Social insurance	1,170,968	1,224,601
Other personnel expenses	122,484	180,695
Personnel expenses	8,481,757	8,736,146
Auditors' fee		
Fee for auditing services	35,000	31,000
Fee for other services	_	_
January 1 to December 31 in CHF	2024	2023
Remainder of liabilities from purchase contract-type leasing transactions and other leasing liabilities not maturing or called within 12 months after the balance sheet date		
Fixed rental contract archive until May 31, 2026	18,065	30,817
Fixed rental contract offices until April 30, 2026	261,765	458,089

January 1 to December 31 in CHF	2024	2023
Notes on extraordinary, non-recurring or out-of-period items in the income statement		
Total out-of-period expenses	_	-
Total out-of-period income	_	-
Total out-of-period result	-	-

\_

Cost reductions as a result of the restructuring are included here.

Fee for auditing services	35,000	31,000
Fee for other services	-	-

January 1 to December 31 in CHF	2024	2023
Remainder of liabilities from purchase contract-type leasing transactions and other leasing liabilities not maturing or called within 12 months after the balance sheet date		
Fixed rental contract archive until May 31, 2026	18,065	30,817
Fixed rental contract offices until April 30, 2026	261,765	458,089
Total non-capitalized leasing liabilities	279,831	488,907

### Net release of hidden reserves

Events after the balance sheet date: none

Liabilities to pension institutions

GOALS

TO

ETHER

#### **Evaluating Research Projects**

For the 2024 financial statements, we have valued research projects. For this valuation, we applied the principle of itemized measurement on those long-term research projects that will incur foreseeable losses on individual trials until the year 2030 (loss-free valuation). Losses arising after this time are not taken into account based on the assumption that additional funds can be generated for those projects and that the funding requirement for trials will be significantly lower in the long run.

We based the research project valuation on the rolling multi-year plan 2025 to 2030, which has been prepared by the respective project managers. This multi-year plan takes into account the expected project funds, the external and internal study costs as well as internal hours, minus any fund withdrawals. Furthermore, we compared the approved and expected non-earmarked federal funding for the years 2025 to 2028 with the sum of staff hours and external costs planned for the loss-making projects minus project funding. The corresponding federal financing for CHF 5.4 million per year is subject to the annual budget decisions of the Federal Assembly.

As of the reporting date, the sum of all trial losses determined in the itemized measurement does not exceed the federal contributions for the years 2025 to 2028. A seasonalized cost presentation was taken into account.

Based on the itemized measurement and the multi-year plan, we created an accrual ensuring that the losses incurred by the long-term research projects are valued as of the reporting date. This accrual is included in the deferred income lines of the balance sheet. It covers the entire sum of all individual study losses incurred between 2025 and 2030, according to the SAKK decentralized multi-year planning as of the end of January 2025.

#### **Miscellaneous information**

The year 2024 brought an extraordinarily positive financial result, especially compared to the previous year. This is mainly thanks to receiving an exceptional legacy donation combined with the good performance of the financial markets.

to the General Assembly of

Opinion

policies.

Basis for Opinion

for our opinion.

ance with these requirements.

our auditor's reports thereon.

### Auditor's Report

GOALS



\_

# Auditor's Report

Statutory Auditor's Report Page 3/3 - Balmer-Etienne AG Bern – 26 March 2025 Balmer Etienne

#### Report on other legal and statutory requirements

In accordance with article 728a paragraph 1 item 3 CO and Swiss Auditing Standard 890, we confirm that an internal control system exists, which has been designed for the preparation of financial statements according to the instructions of the Board.

We further confirm that the proposed appropriation of available earnings complies with Swiss law and the company's articles of incorporation.

We recommend that the financial statements submitted to you be approved.

Berne, 26 March 2025 fco/ere/ros

Balmer-Etienne AG Bern

A. Causcer Fabrizio Conoscenti

Fabrizio Conoscenti Audit Expert Authorised audit expert (Auditor in Charge)

Financial statements 2024



p.p. Elsa Reinhard M A Business and Law, University of Berne Auditor

# **Publishing Details**

GOALS



#### Publisher and point of contact Swiss Group for Clinical Cancer Research SAKK SAKK Competence Center Effingerstrasse 33 3008 Bern Switzerland

Phone +41 31 389 91 91 Media inquiries: media@sakk.ch sakk.ch

SAKK donations account IBAN: CH68 0900 0000 6029 5422 0 PostFinance AG, Mingerstrasse 20, 3030 Bern BIC/SWIFT: POFICHBEXXX Clearing no. (BLZ): 9000 **Design, text and project management** Communications, SAKK Competence Center etextera, Schmitten

Layout, typesetting and proofreading Linkgroup AG, Zurich

**Translations** BMP Translations AG, Basel

**Printed by** Merkur Druck AG, Langenthal

#### About this report

The SAKK Financial Report for 2024 is available on our website at www.sakk.ch/en/annual-report

They are available in German and English. The English version is authoritative.

#### **Annual Portrait**

The Financial Report is published as an addendum to the Annual Portrait. This reports on the events of 2024 and provides an insight into SAKK's activities.





Swiss Group for Clinical Cancer Research SAKK Effingerstrasse 33, 3008 Bern, Switzerland sakk.ch

